U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117045) titled 'Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer' on Aug. 05.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensitivity for detecting pancreatic lesions. This study utilizes the Pancreatic Cancer Detection with Artificial Intellige...